We dont believe in one-size-fits-all protocols
You still need to eat and you need to eat enough
[80] The trial reported cumulative occurrence of major adverse cardiovascular events, a primary end-point event of the trial, for 569 of the 8803 patients in the semaglutide group, which were 6.5% of the participants, and for 701 of the 8801 patients in the placebo group, which were 8% of the participants, showing relative 18.8% less major adverse cardiovascular events, such as death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, occurring for participants who had received semaglutide in the trial relative to those who had received placebo over the course of around 48 months, or 34.213.7 months, which was the mean (SD) total duration of the participants in either group's exposure to the placebo or semaglutide during the trial
FAQs About Semaglutide and Tirzepatide Is tirzepatide stronger than semaglutide
Saxenda and Ozempic are also licensed for different things Saxenda is licensed for weight loss, while Ozempic is licensed to treat type 2 diabetes, although some doctors may prescribe it off-label for weight loss
Complication Sequencing When obesity is the reason for the encounter (e.g., obesity management, bariatric consult), E66.xx is the principal/first-listed diagnosis
